Search
Arcutis Biotherapeutics Inc
ARQTAdd to Watchlist
26.175USD
-0.045-0.17%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
3.27BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of Arcutis Biotherapeutics Inc is 8.25, ranking 48 out of 157 in the Pharmaceuticals industry. The average price target is 30.50, with a high of 37.00 and a low of 29.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
34.625
Target Price
+35.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Arcutis Biotherapeutics Inc
ARQT
8
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Arcutis Biotherapeutics Inc's expected revenue for the next quarter?
Arcutis Biotherapeutics Inc's expected revenue is 117.54M.
What is Arcutis Biotherapeutics Inc's price target?
Analysts forecast that Arcutis Biotherapeutics Inc's price target is USD 30.50, with the highest forecast at USD 37.00 and the lowest forecast at USD 29.00.
How have Arcutis Biotherapeutics IncARQT's recent earnings per share performed?
The market expectation was USD -0.09, while Arcutis Biotherapeutics IncARQT's earnings per share (EPS) for the previous quarter was USD 0.14. EPS for the next quarter is expected at USD 0.03.
What is the analyst rating for Arcutis Biotherapeutics Inc?
Based on the ratings of Arcutis Biotherapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
